Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations
The burden of hepatocellular carcinoma (HCC) is on the rise in the Gulf region, with most patients being diagnosed in the intermediate or advanced stages. Surgery is a treatment option for only a few, and the majority of patients receive either locoregional treatment (percutaneous ethanol injection,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/7/2001 |
| _version_ | 1797608245331755008 |
|---|---|
| author | Jasem Albarrak Humaid Al-Shamsi |
| author_facet | Jasem Albarrak Humaid Al-Shamsi |
| author_sort | Jasem Albarrak |
| collection | DOAJ |
| description | The burden of hepatocellular carcinoma (HCC) is on the rise in the Gulf region, with most patients being diagnosed in the intermediate or advanced stages. Surgery is a treatment option for only a few, and the majority of patients receive either locoregional treatment (percutaneous ethanol injection, radiofrequency ablation, transarterial chemoembolization [TACE], radioembolization, radiotherapy, or transarterial radioembolization) or systemic therapy (for those ineligible for locoregional treatments or who do not benefit from TACE). The recent emergence of novel immunotherapies such as immune checkpoint inhibitors has begun to change the landscape of systemic HCC treatment in the Gulf. The combination of atezolizumab and bevacizumab is currently the preferred first-line therapy in patients not at risk of bleeding. Additionally, the HIMALAYA trial has demonstrated the superiority of the durvalumab plus tremelimumab combination (STRIDE regimen) therapy in efficacy and safety compared with sorafenib in patients with unresectable HCC. However, there is a lack of data on post-progression treatment after first-line therapy with either atezolizumab plus bevacizumab or durvalumab plus tremelimumab regimens, highlighting the need for better-designed studies for improved management of patients with unresectable HCC in the Gulf region. |
| first_indexed | 2024-03-11T05:40:45Z |
| format | Article |
| id | doaj.art-6259e75fd39644bba001261710d17e61 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T05:40:45Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6259e75fd39644bba001261710d17e612023-11-17T16:24:41ZengMDPI AGCancers2072-66942023-03-01157200110.3390/cancers15072001Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and RecommendationsJasem Albarrak0Humaid Al-Shamsi1Kuwait Cancer Control Center, Sabah Health Region, Kuwait City 8WF3+WR8, KuwaitBurjeel Medical City- Burjeel Holding, Abu Dhabi 92510, United Arab EmiratesThe burden of hepatocellular carcinoma (HCC) is on the rise in the Gulf region, with most patients being diagnosed in the intermediate or advanced stages. Surgery is a treatment option for only a few, and the majority of patients receive either locoregional treatment (percutaneous ethanol injection, radiofrequency ablation, transarterial chemoembolization [TACE], radioembolization, radiotherapy, or transarterial radioembolization) or systemic therapy (for those ineligible for locoregional treatments or who do not benefit from TACE). The recent emergence of novel immunotherapies such as immune checkpoint inhibitors has begun to change the landscape of systemic HCC treatment in the Gulf. The combination of atezolizumab and bevacizumab is currently the preferred first-line therapy in patients not at risk of bleeding. Additionally, the HIMALAYA trial has demonstrated the superiority of the durvalumab plus tremelimumab combination (STRIDE regimen) therapy in efficacy and safety compared with sorafenib in patients with unresectable HCC. However, there is a lack of data on post-progression treatment after first-line therapy with either atezolizumab plus bevacizumab or durvalumab plus tremelimumab regimens, highlighting the need for better-designed studies for improved management of patients with unresectable HCC in the Gulf region.https://www.mdpi.com/2072-6694/15/7/2001Gulf regionhepatocellular carcinomaimmune-checkpoint inhibitorslocoregional therapymanagement of HCCsystemic therapy |
| spellingShingle | Jasem Albarrak Humaid Al-Shamsi Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations Cancers Gulf region hepatocellular carcinoma immune-checkpoint inhibitors locoregional therapy management of HCC systemic therapy |
| title | Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations |
| title_full | Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations |
| title_fullStr | Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations |
| title_full_unstemmed | Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations |
| title_short | Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations |
| title_sort | current status of management of hepatocellular carcinoma in the gulf region challenges and recommendations |
| topic | Gulf region hepatocellular carcinoma immune-checkpoint inhibitors locoregional therapy management of HCC systemic therapy |
| url | https://www.mdpi.com/2072-6694/15/7/2001 |
| work_keys_str_mv | AT jasemalbarrak currentstatusofmanagementofhepatocellularcarcinomainthegulfregionchallengesandrecommendations AT humaidalshamsi currentstatusofmanagementofhepatocellularcarcinomainthegulfregionchallengesandrecommendations |